'On standalone basis

Quarter ended September 2025 compared with Quarter ended September 2024.

Net sales (including other operating income) of RPG Life Sciences has increased 5.50% to Rs 181.68 crore.  Operating profit margin has declined from 26.67% to 21.48%, leading to 15.02% decline in operating profit to Rs 39.03 crore.  Raw material cost as a % of total sales (net of stock adjustments) increased from 12.60% to 17.53%.   Purchase of finished goods cost rose from 15.94% to 20.78%.   Employee cost decreased from 20.03% to 19.38%.   Other expenses fell from 23.62% to 21.39%.   

Other income up 134.02% to Rs 4.54 crore.  PBIDT fell 8.98% to Rs 43.57 crore.  Provision for interest fell 29.41% to Rs 0.12 crore.  Loan funds remained nil.  Inventories rose to Rs 106.97 crore as of 30 September 2025 from Rs 99.16 crore as of 30 September 2024.  Sundr...

• 

  (19-Oct-2025)

  JSW Energy

  Sales up 60%, OP up 78%, net down 17%
• 

  (19-Oct-2025)

  Huhtamaki India

  Sales down 4%, but net jumps 214%
• 

  (19-Oct-2025)

  Dixon Technologies (India)

  Net up 72% on inflated base
• 

  (19-Oct-2025)

  Polycab India

  Net up 56% on strong operating show